EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
Do-it-yourself game plans

Stage 4: How do you verify pharmacy and supplier evidence independently?

Dose Diligence research deskSection 02 · Page 6 of 17Last updated 17 Nov 2026

Verify claims against the facility that will actually handle the medicine. FDA states that outsourcing registration and inspections are facility-specific; registration does not establish product approval or compliance with all applicable requirements. FDA registration Q&A.

What belongs in the evidence register?

Use these columns:

Claim | Product/route | Legal entity | Facility | State | Source/document | Source date | Checked date | Evidence status | Reviewer | Open question | Deadline | Decision impact

Recommended evidence statuses are independently verified, supplier-supported but not independently confirmed, missing, adverse evidence requiring assessment, and not applicable.

CheckIndependent actionSuggested procurement response to a gap
Entity identityMatch legal names and addresses across contracts, licences and actual fulfilment documentsResolve mismatches before routing
Pharmacy permissionsSearch the home-state and destination-state boardsExclude unverified states from launch
503B registration, if relevantCheck FDA's register for the precise facilityDo not use a corporate-group entry as a substitute
Inspection and enforcement historySearch FDA compounding actions, warning letters and state recordsObtain responses and qualified interpretation
Corrective actionsRequest evidence supporting closure or effectivenessDo not accept a promise of future remediation as completed work
Product provenanceReconcile seller, source, product identifier and lot documentationEscalate unexplained supply-chain breaks
Storage and transportReview product-specific handling and shipping qualification evidenceRequire a documented excursion process
Recall readinessRun a tabletop exercise connecting product/lot to affected ordersFix missing traceability before scale

Useful primary-source starting points are FDA's registered outsourcing facilities, compounding inspections and actions, and wholesale-distributor reporting information. The outsourcing register reviewed here was updated November 6, 2026; preserve that source date alongside your own review date.

How should you interpret an FDA Form 483?

A Form 483 records inspection observations; it is not a final agency determination of a violation. FDA considers it together with the inspection report, evidence and company responses. Request the complete sequence and have a qualified reviewer assess relevance to the proposed supply. FDA Form 483 FAQ.

Conversely, do not turn an unsuccessful public-record search into a positive quality conclusion. Record exactly what was searched and what remains unavailable.

Why does “nationwide pharmacy coverage” need checking?

Build a facility-by-state matrix rather than accepting a national marketing claim. California, for example, requires the relevant nonresident sterile-compounding licence for a nonresident pharmacy compounding sterile products for shipment into the state. Texas distinguishes nonresident pharmacy requirements and states that a delinquent licence requires cessation of shipping prescriptions into Texas until active status is restored. California pharmacy lawbook; Texas nonresident requirements.

Use one row per actual fulfilling location and destination:

Facility | Destination | Required permission | Licence/status | Expiry | Product accepted | Capacity confirmed | Delivery tested | Launch decision

Keep prescriber authorisation and telehealth requirements in a separate legal workstream; pharmacy coverage is not the same question.

What should you do about DSCSA?

Ask counsel to map responsibilities to each party's actual supply-chain role and transaction. FDA's current exemption page extends certain requirements for qualifying small dispensers to November 27, 2027. Its definition uses the owning company's pharmacist/pharmacy-technician employee count as of November 27, 2026—not the clinic's number of prescribers. This is not an exemption from every DSCSA obligation. FDA exemptions. (fda.gov)

Request a written responsibility matrix covering trading-partner verification, applicable transaction records, suspect-product handling, recall support and record access. For any claimed exemption, retain its scope, basis and expiration.

How should you evaluate cold chain, packaging and dosing instructions?

Use the exact presentation's current label and the supplier's qualified procedures—not a generic GLP-1 temperature rule. For example, Zepbound's prescribing information has presentation-specific storage instructions and prohibits use after freezing. Current prescribing information.

For any compounded preparation that survives eligibility review, obtain independent clinical/pharmacy review of concentration, volume, labelled instructions, supplied measuring device and patient education. FDA has reported dosing errors involving varying concentrations and confusion among milligrams, millilitres and syringe units. FDA dosing-error alert.

Do not equate a certificate of analysis with complete assurance about the finished preparation, patient instructions or distribution process. Treat it as one item in a broader quality review.

Stage 4 exit document: an accepted evidence register and a launch matrix that identifies unsupported states, products or facilities explicitly.

Explore the table row by row

A working view of the research

Entity identity

Independent action
Match legal names and addresses across contracts, licences and actual fulfilment documents
Suggested procurement response to a gap
Resolve mismatches before routing

Answers stay in this session unless you choose to save. No account needed.

Sources cited on this page

  1. fda.gov · Source 1 ↗https://www.fda.gov/drugs/human-drug-compounding/questions-and-answers-outsourcing-facility-registration
  2. fda.gov · Source 2 ↗https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
  3. fda.gov · Source 3 ↗https://www.fda.gov/drugs/human-drug-compounding/compounding-inspections-recalls-and-other-actions
  4. fda.gov · Source 4 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act/annual-reporting-prescription-drug-wholesale-distributors-and-third-party-logistics-providers
  5. fda.gov · Source 5 ↗https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-references/fda-form-483-frequently-asked-questions
  6. pharmacy.ca.gov · Source 6 ↗https://www.pharmacy.ca.gov/laws_regs/lawbook
  7. pharmacy.texas.gov · Source 7 ↗https://www.pharmacy.texas.gov/licensees/nonresident-pharmacy-requirements.asp
  8. fda.gov · Source 8 ↗https://www.fda.gov/drugs/drug-supply-chain-security-act-dscsa/exemptions-under-drug-supply-chain-security-act
  9. uspl.lilly.com · Source 9 ↗https://uspl.lilly.com/zepbound/zepbound.html
  10. fda.gov · Source 10 ↗https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
Section sources →